We are live on ! Find out more

Johnson & Johnson

JNJ

Market cap $688B

285.82 USD

+2.30

0.81%

At close Updated Nov 13, 12:16 PM EST

1 day

0.81%

5 days

2.81%

1 month

14.97%

3 months

9.06%

6 months

24.04%

Year to date

37.84%

1 year

46.39%

5 years

74.79%

10 years

145.13%

About: Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Employees: 140,800

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 49.3%

Neutral 42.4%

Negative 8.3%

The Big 3: JNJ, LLY, AAPL

Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks including Johnson & Johnson (JNJ), Eli Lilly (LLY) and Apple (AAPL).

The Big 3: JNJ, LLY, AAPL

Zacks Investment Research

Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?

Johnson & Johnson (JNJ) Up 10.4% Since Last Earnings Report: Can It Continue?

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson ("J&J" or the "Company") (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

The Motley Fool

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

Johnson & Johnson maintains a massive healthcare presence across both innovative medicines and advanced medical technologies. Eli Lilly is currently defined by explosive growth in the metabolic health market, particularly through its obesity and diabetes treatments.

Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?

The Motley Fool

Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?

Johnson & Johnson is expertly handling a recent major patent cliff. Recent launches should help boost sales growth over the next few years.

Johnson & Johnson Sees a Path to Double-Digit Growth by 2030. Is the Dividend King a Buy?

Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case

DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541 for a sum total of $3,325,631 against Johnson & Johnson on behalf of the family of Winifred “Missy” Haddad, a Massachusetts woman who developed mesothelioma after years of using the company's talcum-based baby powder. Jurors in Suffolk County Superior Court found that Johnson & Johnson's baby.

Massachusetts Woman's Family Awarded $3.3 Million Against Johnson & Johnson in Mesothelioma Case

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Johnson & Johnson (“J&J” or the “Company”) (NYSE: JNJ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ

Zacks Investment Research

J&J's Oncology Sales Surge So Far in 2026: What Lies Ahead?

J&J's oncology sales surge 16.8% to $22 billion in the first nine months of 2026, fueled by blockbuster drugs and new launches.

J&J's Oncology Sales Surge So Far in 2026: What Lies Ahead?

24/7 Wall Street

$300,000 in Duke Energy, Philip Morris and Johnson & Johnson: Here's What It Pays

One utility, one tobacco giant, and one healthcare Dividend King each get $100,000 to see who earns the most. The ranking surprises, and one stock's 64-year raise streak comes with the lowest payout of the three.

$300,000 in Duke Energy, Philip Morris and Johnson & Johnson: Here's What It Pays

J&J eyes US nod for Caplyta in bipolar mania after second trial win

Johnson & Johnson said on Tuesday its drug Caplyta eased manic symptoms better than placebo in a second late-stage study of patients with bipolar I disorder, paving the ‌way for a planned US regulatory filing.

J&J eyes US nod for Caplyta in bipolar mania after second trial win

See News Rankings

Price charts implemented using Lightweight Charts™